Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €21.05 EUR
Change Today +0.31 / 1.49%
Volume 3.3K
As of 10:09 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

revenio group oyj (REG1V) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/13/15 - €24.95
52 Week Low
10/16/14 - €13.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for REVENIO GROUP OYJ (REG1V)

Related News

No related news articles were found.

revenio group oyj (REG1V) Related Businessweek News

No Related Businessweek News Found

revenio group oyj (REG1V) Details

Revenio Group Oyj designs, manufactures, and sells medical instruments used for measuring intraocular pressure and bone density in Finland and internationally. It provides tonometers for intraocular pressure screening; ultrasound-based detection device for the screening, diagnosis, and monitoring of osteoporosis; and disposable probes, as well as bone density measurement devices. The company serves pharmacy chains, gynecologists, orthopedists, clinics, pharmaceutical plants, and screening companies. Revenio Group Oyj is headquartered in Vantaa, Finland.

29 Employees
Last Reported Date: 04/24/15

revenio group oyj (REG1V) Top Compensated Officers

Chief Executive Officer, President and Segmen...
Total Annual Compensation: €319.1K
Compensation as of Fiscal Year 2014.

revenio group oyj (REG1V) Key Developments

Revenio Signs a Distribution Contract with Topcon Medical Systems

In Finland, Revenio has signed a distribution contract with Topcon Medical Systems. Topcon is the distributor of ten big American optician chains. Revenio wants to sell its tonometers to the US.

Revenio Group Corporation Appoints Robin Pulkkinen as CFO and Member of the Management Group as of July 15, 2015

Revenio Group Corporation has appointed M.Sc. Econ. Robin Pulkkinenas as CFO and member of the management group as of July 15, 2015. Pulkkinen reports to the Revenio Group's President and CEO Olli-Pekka Salovaara. Pulkkinen joins Revenio from the position of Symbio's EMEA area CFO. Prior to Symbio Pulkkinen has held several top management positions in international corporations both in Finland and Canada having solid experience in various roles of financial management.

Revenio Group Corporation Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

Revenio Group Corporation reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net sales from continuing operations of EUR 4.6 million compared to EUR 3.7 million for the same period a year ago. EBITDA from continuing operations was EUR 1.5 million compared to EUR 1.2 million last year. Operating profit from continuing operations was EUR 1.4 million compared to EUR 1.1 million last year. Pre-tax profit from continuing operations was EUR 1.6 million compared to EUR 1.1 million last year. Net profit from continuing operations was EUR 1.2 million or EUR 0.15 per diluted share compared to EUR 1.0 million or EUR 0.12 per undiluted and diluted share last year. Net profit was EUR 1.5 million compared to EUR 1.0 million last year. Net profit attributable to parent company shareholders was EUR 1.5 million compared to EUR 1.0 million last year. Cash flow from operations was EUR 3.1 million compared to EUR 0.1 million a year ago. The group's purchases of PPE and intangible assets totaled EUR 0.5 million compared to EUR 0.3 million a year ago. Gross capital expenditure was EUR 0.5 million compared to EUR 0.3 million a year ago. Return on investment was 32.6% compared to 26.3% last year. Return on equity was 55.2% compared to 27.4% last year. For the year 2015, the net sales and operating profit of Icare are expected to grow from last year. Investments in new business operations related to health tech, which have an impact on consolidated operating profit and cash flow. No significant investments will be made in 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REG1V:FH €21.05 EUR +0.31

REG1V Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for REG1V.
View Industry Companies

Industry Analysis


Industry Average

Valuation REG1V Industry Range
Price/Earnings 40.6x
Price/Sales 9.2x
Price/Book 15.6x
Price/Cash Flow 498.2x
TEV/Sales 9.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REVENIO GROUP OYJ, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at